SCHEMBL5331546

SCHEMBL5331546

Cn1ncnc1Cc1ccccc1N1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMARCA2 P51531 1/20 0.46
SMARCA4 P51532 1/20 0.46
PBRM1 Q86U86 1/20 0.46
CKS1B P61024 2/20 0.46
SKP1 P63208 2/20 0.46
SKP2 Q13309 2/20 0.46
ACHE P22303 2/20 0.46
KIT P10721 1/20 0.44
GPR119 Q8TDV5 6/20 0.43
MAP4K4 O95819 1/20 0.42
BACE1 P56817 2/20 0.42
POLB P06746 1/20 0.42
TP53 P04637 1/20 0.42
THRB P10828 1/20 0.42
NPC1 O15118 1/20 0.42
LMNA P02545 1/20 0.42
NR2F2 P24468 1/20 0.42
HTT P42858 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5343839 0.83 ACHE (0.48) SMARCA2SMARCA4PBRM1CKS1BSKP1
SCHEMBL7981893 0.81 GAA (0.56) SMARCA2SMARCA4PBRM1CKS1BSKP1
SCHEMBL14355879 0.80 NCF1 (0.50)
SCHEMBL8881052 0.79 ACHE (0.48) SMARCA2SMARCA4PBRM1CKS1BSKP1
SCHEMBL615074 0.79 CHRM2 (0.52) SMARCA2SMARCA4PBRM1CKS1BSKP1
SCHEMBL416461 0.78 ACHE (0.51) SMARCA2SMARCA4PBRM1CKS1BSKP1
SCHEMBL110163 0.78 NCF1 (0.51) SMARCA2SMARCA4PBRM1CKS1BSKP1
SCHEMBL28708137 0.78 GPR119 (0.49) SMARCA2SMARCA4PBRM1CKS1BSKP1
SCHEMBL5339274 0.77 ACHE (0.47) SMARCA2SMARCA4PBRM1CKS1BSKP1
SCHEMBL8567620 0.77 ACHE (0.47) SMARCA2SMARCA4PBRM1CKS1BSKP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7291619-B2 Melanocortin receptor agonists ELI LILLY AND COMPANY (US) 2007-11-06 US disclosed
US-7291619-B2 Melanocortin receptor agonists ELI LILLY AND COMPANY (US) 2007-11-06 US disclosed
EP-1368340-B1 PIPERAZINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS LILLY CO ELI (US) 2005-08-10 EP disclosed
US-20040092507-A1 Melanocortin receptor agonists ELI LILLY AND COMPANY 2004-05-13 US disclosed
EP-1368340-A1 PIPERAZINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2003-12-10 EP disclosed
WO-2002059108-A1 MELANOCORTIN RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2002-08-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092507-A1 Melanocortin receptor agonists MC1R, MC4R, MC5R SMARCA2 4437/4885SMARCA4 4290/4885PBRM1 4413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.